ALK and neuroblastoma: Activated ALK acts as an oncogenic driver in anaplastic large cell lymphoma (ALCL), non-small cell lung carcinoma (NSCLC) and neuroblastoma and is linked to poor clinical outcome, especially in high risk neuroblastoma (8, 16, 51).